Zylox-Tonbridge Sets Governance Rules for Board Nomination Committee

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) has provided an announcement.

Zylox-Tonbridge Medical Technology Co., Ltd. has formalized detailed terms of reference for its Nomination Committee, specifying that it must comprise at least three directors, with a majority being independent non-executive directors and at least one member of a different gender. The framework also requires members to disclose any financial interests or potential conflicts of interest, mandates recusal from related decisions, and ties committee tenure to board service.

The rules set out clear procedures for appointing, removing, and replacing committee members, and state that anyone leaving the board automatically ceases to serve on the Nomination Committee. They also define the committee’s leadership and support structure, setting the chairman as either the board chair or an independent non-executive director, appointing the company secretary as committee secretary, establishing quorum and voting rules, and requiring at least one meeting per year, which can be attended physically or via electronic means.

The most recent analyst rating on (HK:2190) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H

Zylox-Tonbridge Medical Technology Co., Ltd. operates in the medical technology sector, with a corporate governance structure overseen by a board of directors and specialized committees. The company emphasizes independent oversight and diversity in its board committees, reflecting a focus on governance standards important to investors and regulators.

Average Trading Volume: 700,433

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.31B

See more data about 2190 stock on TipRanks’ Stock Analysis page.